Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

IDEA-033 yields pain reduction in patients with osteoarthritis of the knee

Aug. 10, 2006

EVT-101 completes phase I testing

Aug. 10, 2006

NovaDel begins bioequivalence trial for proprietary zolpidem oral spray

Aug. 10, 2006

FemmePharma opens IND for topical treatment for breast pain

Aug. 10, 2006

Novel PARP-1 inhibitor protects Huntington's disease cells from oxidative damage in vitro

Aug. 9, 2006

Diamyd sublicenses use of GAD65 gene to Neurologix for Parkinson's disease

Aug. 9, 2006

Phase I study for NGX-426, oral prodrug of tezampanel

Aug. 9, 2006

Allon seeks clearance to add Canadian sites to phase II study of AL-208

Aug. 9, 2006

Betaseron approved in Canada for earliest stages of MS

Aug. 8, 2006

V-3381 studied in phase IIa trial for diabetic neuropathic pain

Aug. 8, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...